



National Audit Office

From COVID-19 to Net Zero: How can regulation respond to change?

21 September 2021

NAO good practice guide: Principles of effective regulation



Today's programme and speakers

1. Keynote speakers:
 - **Gareth Davies**, Comptroller & Auditor General and head of the National Audit Office
 - **Dame Glenys Stacey**, Chair Designate, Office for Environmental Protection & Chief Regulator, Ofqual
2. Q&A with Gareth and Dame Glenys
3. Panel member introductory remarks:
 - **Chris Carr**, Director of Better Regulation, Department for Business, Energy and Industrial Strategy
 - **Rachel Arrundale**, Deputy Policy Director, Medicines and Healthcare products Regulatory Agency
 - **Will Hayter**, Head of the Digital Markets Unit, Competition and Markets Authority
 - **Tim Johnson**, Policy Director, Civil Aviation Authority
 - **Martin Lodge**, Professor of Political Science and Public Policy, London School of Economics
4. Panel discussion and Q&A

Housekeeping

- Please feel free to ask questions for our speakers using the chat function, which will be visible to all of today's presenters. We will try to answer as many as we can.
- The event is being recorded, and we plan to make the video available on the NAO website.
- We will write up a note summarising the key themes from the event and make this available online.

How can regulation respond to change?

Chris Carr, Director, Better Regulation Executive, BEIS

NAO Webinar 21 September 2021



Introduction

There are four main ways in which BRE helps UK regulation respond to change:

- **Having the Right Metric** - Measuring and scoring regulatory impacts and – important! – keeping the methods up-to-date.
- **Horizon Scanning** - Keeping abreast of changes in technology and society.
- **Promoting best practice among regulators** - Making sure regulators are at the cutting edge of change.
- **Unlocking the benefits of technology** - Using technology to make navigating regulation easier for government, regulators and the regulated.

In addition, we also look for **outcomes-based regulation** where sensible; we build on the **anticipatory approach**, identifying regulatory problems before they become critical; and **learn from our international peers**. This may include international collaboration, to ensure we take account of best practice.

Having the Right Metric

We are reviewing the Better Regulation Framework. As part of this review, we are exploring how the Government could change the metrics it uses to measure the impact of regulation. These metrics are used to decide whether to implement a regulation, to evaluate its effectiveness and to report on the impact of the Government's intervention on business.

The right metric:	A less effective metric risks:
<ul style="list-style-type: none">• Enables Government to understand the impacts of its regulation;• Can be calculated consistently across different sectors;• Is clear in scope, so that decision-makers understand what it does (and does not) measure;• Measures impacts that are important to Government and stakeholders.	<ul style="list-style-type: none">• Creating perverse incentives for decision makers (e.g. a metric that does not differentiate between small costs affecting many businesses and large costs affecting a smaller number, could lead to disregarding the needs of the majority of businesses, in favour of impacts with a higher OIXO score affecting few businesses.);• (When used as part of a decision-making process.) Impeding action on important societal issues, particularly where the benefits are financially difficult to quantify (e.g. curbing the gambling industry, addressing net zero, may be expensive); and• Misrepresenting costs to business, for example by not taking into account the indirect costs brought about by behavioural changes caused by a policy.

Horizon Scanning



- In its 2019 White Paper “**Regulation for the Fourth Industrial Revolution**”, the government recognised the need for regulation to unlock new innovations.
- The **Regulatory Horizons Council** was established as an independent expert body to identify the implications of technological innovation and advise on the regulatory reform needed to support its rapid and safe introduction.
- To match the pace of technological change, the Council works in an agile way, identifying areas for change, quickly engaging with sector experts and producing timely reports. It has recently published recommendations on the future regulation of: fusion energy; genetic technologies; and medical devices; with a report on drones to follow.
- In its next wave of work the Council is considering: Pro-Innovation Regulatory Principles; AI in Healthcare; Neurotechnologies; and the Hydrogen Economy.

Enabling innovation by getting regulation right

- The Regulators' Pioneer Fund (RPF) helps regulators develop new ways to reduce regulatory barriers to innovation and help businesses get their innovative products and services to market faster.
- During 2018-20, the RPF invested ~£10 million in 14 regulator-led projects. Examples of positive advances from this include:
 - **Medicines and Healthcare products Regulatory Agency** developed unique synthetic datasets, which mimic real patient data with very high fidelity. These datasets will help researchers and firms develop and validate their innovative AI and medical devices.
 - **Civil Aviation Authority** used RPF funding to establish a regulatory sandbox, working with innovative companies to explore regulatory barriers and test innovations in a safe environment.
- On 16 September 2021, BEIS confirmed the 21 projects selected for a new £3.7 million round of the RPF.

Unlocking the benefits of technology

A key challenge for HMG is to improve business access to regulation and simplify paths for innovators to create new products and services. Technology can help to deliver these outcomes, with a range of RegTech solutions already emerging. To provide these types of solution at scale, access is required to the structure and operation of UK regulation as data. The Better Regulation Executive is developing new tools to enable these outcomes:

- An **Open Regulation Platform (ORP)** will publish UK business regulations as enriched machine-readable data and making it available through an open-access API. Using the ORP, government, businesses and third parties will be able to develop tools to help navigate and comply with regulatory obligations in smarter and less burdensome ways.
- A **Digital Regulation Navigator (DRN)** will be the first consumer of ORP data. It will help businesses (especially Small and Medium-sized Enterprises and microbusinesses) to navigate the complex regulatory landscape and aid compliance.
- A **Smart Regulation (Smartreg) tool** will provide a digital service for policy makers, lawyers and analysts using Natural Language Processing (NLP), to help them understand better the individual and cumulative burden of the stock of regulation.

Thank you.

Chris Carr, Director, BRE

chris.carr@beis.gov.uk





Medicines & Healthcare products
Regulatory Agency

NAO Regulation Event – MHRA Panel Session

Rachel Arrundale, Deputy Director, Policy: Tuesday 21 September 2021



The change environment

Science and technology advances – realising the potential for transformative new treatments

The IMMDSR highlighting serious lessons and areas for improvement in standards


EU Exit, establishing MHRA as a standalone Agency, making most of opportunities

... **Covid 19 Pandemic**

EMBARGOED UNTIL 00.01 HOURS ON 8 JULY 2020

First Do No Harm

The report of the Independent
Medicines and Medical Devices
Safety Review



Covid 19 Flexibilities



Guidance

MHRA regulatory flexibilities resulting from coronavirus (COVID-19)

Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak
<https://www.gov.uk/government/collections/mhra-guidance-on-coronavirus-covid-19>



Covid 19 Vaccine development

Rapid reviews of clinical trials applications to support manufacturers and researchers on potential treatments for COVID-19. Clinical trial approval time reduced from c19 to 8 days

Rolling reviews of applications for authorisation: and open invitation for those developing Covid 19 vaccines to come for early regulatory advice

Regulatory development: use of R174 emergency authorisation – and new Statutory Instrument to “back up” use of that regulation.

Everything ready for the time a vaccine could be approved:

- Pharmacovigilance and surveillance plans and mechanisms in place
- Inspections: advance consideration of GxP issues, ensuring relevant inspections carried out in advance
- Readiness for batch testing - tech transfers completed and ready to go
- Communications and policy advice prepared ...

The Future – Our Delivery Plan

Our goals



Scientific innovation

2. Deliver public health impact, world-leading research innovation and a unique proposition
3. Overhaul the clinical trials system to support innovation and reduce time to approval



Healthcare access

4. Develop and deliver our future strategy and approach for access to medicines and devices
5. Establish a new medical devices legislative framework to support safe innovation and ongoing access to products



Patient safety

6. Deliver a more responsive safety surveillance and risk management system, for all medical products, to keep patients safe
7. Deliver innovative interventions to ensure the UK has a secure supply chain providing high quality products



Priority for all staff

1. Deliver better patient and public involvement to ensure we put patients first



Dynamic organisation

8. Deliver our Transformation Programme to make us a truly world-leading, innovative regulator
9. Deliver a programme to enhance our leadership capability and to attract, retain and develop talent so that we can fuel innovation and drive change



Collaborative partnerships

10. Leverage international partnerships to drive better outcomes
11. Leverage UK healthcare system partnerships to integrate processes and drive better outcomes.
12. Build public and stakeholder trust in our organisation through a programme of proactive and innovative communications



Financial sustainability

13. Establish a new business model for the future that increases income, reduces costs and improves productivity
14. Deliver an optimised IT infrastructure to improve our service and reduce our costs with fewer digital technologies

Contact

Rachel.Arrundale@mhra.gov.uk

© Crown copyright 2020

Produced by the Medicines and Healthcare products Regulatory Agency

You may re-use this information (excluding logos) with the permission from the Medicines and Healthcare products Regulatory Agency, under a Delegation of Authority. To view the guideline, visit, <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information> or email: copyright@mhra.gov.uk.

Where we have identified any third-party copyright material you will need to obtain permission from the copyright holders concerned.

Thank you



National Audit Office



Follow the
NAO on Twitter
[@NAOorguk](https://twitter.com/NAOorguk)



Follow the NAO
on LinkedIn
[www.linkedin.com/
company/naoorguk](https://www.linkedin.com/company/naoorguk)



View our Commercial
Hub pages
[https://www.nao.org.uk/
knowledge/commercial/](https://www.nao.org.uk/knowledge/commercial/)



All reports are
available at
www.nao.org.uk



If you are interested in
the NAO's work and
support for Parliament
please contact:
parliament@nao.org.uk